JP3805900B2 - Antifungal agent and composition containing the same - Google Patents
Antifungal agent and composition containing the same Download PDFInfo
- Publication number
- JP3805900B2 JP3805900B2 JP23355798A JP23355798A JP3805900B2 JP 3805900 B2 JP3805900 B2 JP 3805900B2 JP 23355798 A JP23355798 A JP 23355798A JP 23355798 A JP23355798 A JP 23355798A JP 3805900 B2 JP3805900 B2 JP 3805900B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- present
- trifluoromethyl
- antifungal agent
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003429 antifungal agent Substances 0.000 title claims description 14
- 229940121375 antifungal agent Drugs 0.000 title claims description 14
- 239000012871 anti-fungal composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229940125904 compound 1 Drugs 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 8
- 229940126214 compound 3 Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229940125898 compound 5 Drugs 0.000 claims description 5
- HKGXURMHVYTERG-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(CN(C)CC(=C)C2=CC(=CC=C2)C(F)(F)F)C=C1 Chemical compound C(C)(C)(C)C1=CC=C(CN(C)CC(=C)C2=CC(=CC=C2)C(F)(F)F)C=C1 HKGXURMHVYTERG-UHFFFAOYSA-N 0.000 claims description 3
- BYHAYBKCVMOBEJ-SOFGYWHQSA-N CC(C#C/C=C/CN(C)CC(=C)C1=CC(=CC=C1)C(F)(F)F)(C)C Chemical compound CC(C#C/C=C/CN(C)CC(=C)C1=CC(=CC=C1)C(F)(F)F)(C)C BYHAYBKCVMOBEJ-SOFGYWHQSA-N 0.000 claims description 3
- 238000007239 Wittig reaction Methods 0.000 claims description 3
- OVEVFKCCMZZTBB-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(CN(C)CC(=C)C2=C(C=CC(=C2)F)F)C=C1 Chemical compound C(C)(C)(C)C1=CC=C(CN(C)CC(=C)C2=C(C=CC(=C2)F)F)C=C1 OVEVFKCCMZZTBB-UHFFFAOYSA-N 0.000 claims description 2
- YEBRVVGRKKLUTR-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CN(C)CC(=O)C2=CC(=CC=C2)C(F)(F)F Chemical compound CC(C)(C)C1=CC=C(C=C1)CN(C)CC(=O)C2=CC(=CC=C2)C(F)(F)F YEBRVVGRKKLUTR-UHFFFAOYSA-N 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- MPTQDBVLGAVFLG-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(CN(C)CC(=O)C2=C(C=CC(=C2)F)F)C=C1 Chemical compound C(C)(C)(C)C1=CC=C(CN(C)CC(=O)C2=C(C=CC(=C2)F)F)C=C1 MPTQDBVLGAVFLG-UHFFFAOYSA-N 0.000 claims 1
- 208000010195 Onychomycosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 201000005882 tinea unguium Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000000843 anti-fungal effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- -1 4-tertiary-butylbenzyl Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000006216 vaginal suppository Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZSHCHOYJMLEAOX-UHFFFAOYSA-N 1-(4-tert-butylphenyl)-n-methylmethanamine Chemical compound CNCC1=CC=C(C(C)(C)C)C=C1 ZSHCHOYJMLEAOX-UHFFFAOYSA-N 0.000 description 2
- TZIYNLSEBAYCBZ-UHFFFAOYSA-N 2-bromo-1-[3-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=CC(C(=O)CBr)=C1 TZIYNLSEBAYCBZ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 201000009862 superficial mycosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- XQRHBYHDDOJZTM-FNORWQNLSA-N (e)-n,6,6-trimethylhept-2-en-4-yn-1-amine Chemical compound CNC\C=C\C#CC(C)(C)C XQRHBYHDDOJZTM-FNORWQNLSA-N 0.000 description 1
- SFUWMFXQRHHPJP-UHFFFAOYSA-N 2-bromo-1-(2,5-difluorophenyl)ethanone Chemical compound FC1=CC=C(F)C(C(=O)CBr)=C1 SFUWMFXQRHHPJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- JRPOUCVBNWLZPA-FNORWQNLSA-N CC(C#C/C=C/CN(CC(=O)C1=CC(=CC=C1)C(F)(F)F)C)(C)C Chemical compound CC(C#C/C=C/CN(CC(=O)C1=CC(=CC=C1)C(F)(F)F)C)(C)C JRPOUCVBNWLZPA-FNORWQNLSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は抗真菌剤に好適な、新規含フッ素化合物に関する。
【０００２】
【従来の技術】
水虫に代表される表在性真菌症は、生活が西洋化して靴の着用時間が増加したのに相まって、未だに確実な治療法及び治療薬が見いだされていないこともあり、現代に於ける克服されていない疾病の一つに数えられている。その為、抗真菌作用について、多くの化合物がスクリーニングをかけられた。しかしながら、ｉｎ ｖｉｔｒｏ或いは動物レベルに於いて活性が見いだされた物質でも、実際の臨床段階においてはドロップアウトするものが少なくなく、満足いく結果は今のところ得られたものは極めて少ない。即ち、新規の抗真菌作用を有する母核の発見が待たれていた。この様な状況は、表在性真菌に止まらず、カンジダ・アルビカンスやアスペルギルス・ニガー等の深在性真菌症に至っては毒性が極めて高く、効果がわずかでしかない、アンホテリシンＢを使わざるを得ない極めて深刻な状況にある。即ち、新規母核を有する抗真菌剤の開発が望まれていた。
【０００３】
一方、後記一般式（Ｉ）に表される化合物は、何れも文献未記載の化合物であり、従って、この様な化合物が優れた抗真菌作用を有することは全く知られていなかった。
【０００４】
【発明が解決しようとする課題】
本発明は、この様な状況下に為されたものであり、抗真菌作用を有する新規母核の化合物を見いだすことを課題とする。
【０００５】
【課題の解決手段】
この様な状況に鑑みて、本発明者らは抗真菌作用を有する新規母核の化合物を求めて鋭意研究努力を重ねた結果、一般式（Ｉ）に表される化合物、中でも一般式（ＩＩ）に表される化合物及び／又は生理的に許容されるその塩にその様な作用を見いだし、発明を完成させるに至った。以下、本発明について実施の形態を中心に詳細に説明を加える。
【０００６】
【化１１】
（但し、式中Ｒ１はフッ素原子を含有する芳香族炭化水素基を表し、Ｒ２は炭素数１〜４のアルキル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【０００７】
【化１２】
（但し、式中Ｘはフッ素原子又はトリフルオロメチル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【０００８】
【発明の実施の形態】
（１）本発明の一般式（ＩＩＩ）及び／又一般式（ＩＶ）に表される化合物
本発明の一般式（ＩＩＩ）及び／又は一般式（ＩＶ）に表される化合物は、一般式（Ｉ）及び／又は一般式（ＩＩ）の化合物を製造する際の重要な反応中間体である。このものをヴィティヒ反応に付すことにより、本発明の一般式（Ｉ）乃至は一般式（ＩＩ）に表される化合物を製造することが出来る。本発明においては、一般式（ＩＩＩ）に表される化合物の内、側鎖を特定した一般式（ＩＶ）の化合物が特に好ましい。又、ハロゲン原子としては塩素原子が特に好ましい。又、この化合物は反応式１に示す如く、芳香族化合物乃至はそのハロゲン化物をルイス酸の存在下アセチル化ししかる後にこのアセチル基のメチルの水素原子をハロゲン原子で置換し、このものと対応するアミンとをアルカリ存在下、縮合する事により製造できる。これらの化合物は何れも文献未記載の新規化合物である。又、本発明のこの様な化合物として特に好ましいものは、２−［Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチルアミノ］−３’−（トリフルオロメチル）アセトフェノン（化合物４）、トランス−２−［Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）メチルアミノ］−３’−（トリフルオロメチル）アセトフェノン（化合物５）及び２−［Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチルアミノ］−２’，５’−ジフルオロアセトフェノン（化合物６）が挙げられる。
【０００９】
【化１３】
（但し、式中Ｒ１はフッ素原子を含有する芳香族炭化水素基を表し、Ｒ２は炭素数１〜４のアルキル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【００１０】
【化１４】
（但し、式中Ｘはフッ素原子又はトリフルオロメチル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【００１１】
【化１５】
【００１２】
【化１６】
【００１３】
【化１７】
【００１４】
【化１８】
（但し、式中Ｘはフッ素原子又はトリフルオロメチル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【００１５】
（２）本発明の一般式（Ｉ）、一般式（ＩＩ）に表される化合物
本発明の一般式（Ｉ）、一般式（ＩＩ）に表される化合物は、上記一般式（ＩＩＩ）、一般式（ＩＶ）に表される化合物を、メチルトリフェニルホスホニウムブロミドとブチルリチウムで処理すること、即ち、ウィッティヒ反応に付すことにより得ることが出来る。本発明に於いて、一般式（Ｉ）で表される化合物の内、一般式（ＩＩ）で表される限定された化合物群が好ましい。更に、フッ素原子の含有形態としては、フッ素原子そのものを置換基に用いることやトリフルオロメチル基を置換基として用いることが好ましい。これはこの様な化合物群が優れた抗真菌活性を有するからである。この様な化合物を具体的に例示すれば、例えばＮ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物１）、トランス−Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物２）、Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−（２，５−ジフルオロフェニル）−２−プロペニルアミン（化合物３）等が例示できる。これらのものは、通常の方法に従って塩へと導くことが出来る。即ち、水系或いは非水系溶媒中で対応する酸を添加することにより塩とすることが出来る。本発明で好ましい塩の種類としては、例えば、塩酸、硫酸、燐酸、硝酸などの鉱酸塩、酢酸、シュウ酸、マレイン酸、フマル酸等の有機酸塩等が例示でき、この中では塩酸塩が特に好ましい。これは、安定性と経済性に優れるからである。かくして得られた一般式（Ｉ）、一般式（ＩＩ）に表される化合物及び／又はその塩は、優れた抗真菌作用を有するため、本発明の抗真菌剤として使用することが出来る。又、本発明の抗真菌剤は安全性にも優れるため、その投与経路は問わない。本発明の化合物の抗真菌剤としての投与量は、患者の状態や症状により異なるが、例えば、経口投与や注射による投与であれば、成人１日、１〜１００００ｍｇを１回乃至は数回に分けて投与するのが好ましく、皮膚外用剤であれば０．１〜１０重量％含有するものを適量塗布するのが好ましく、膣座剤であれば、０．１〜１０重量％含有する座剤を１回乃至は数回取り替えて投与するのが好ましい。
【００１６】
（３）本発明の医薬組成物
本発明の医薬組成物は、上記本発明の抗真菌剤を含有することを特徴とする。後記実施例に示す如く、本発明の抗真菌剤は優れた抗真菌作用を有するため、本発明の医薬組成物は、表在性真菌症や深在性真菌症の治療や悪化の予防、再発防止に大変有益である。本発明の医薬組成物としては、例えば、液剤、クリーム、軟膏などの皮膚外用剤、錠剤、カプセル剤、散剤などの経口製剤、注射剤、膣座剤等の剤形が好ましく例示できる。本発明の医薬組成物には、上記抗真菌剤以外に、通常医薬組成物で使用される任意成分を含有することが出来る。この様な任意成分としては、例えば、経口製剤や注射剤であれば、賦形剤、結合剤、被覆剤、滑沢剤、糖衣剤、崩壊剤、増量剤、矯味矯臭剤、乳化・可溶化・分散剤、安定剤、ｐＨ調整剤、等張剤等が例示でき、皮膚外用剤や膣座剤であれば、ワセリンやマイクロクリスタリンワックス等のような炭化水素類、ホホバ油やゲイロウ等のエステル類、牛脂、オリーブ油等のトリグリセライド類、セタノール、オレイルアルコール等の高級アルコール類、ステアリン酸、オレイン酸等の脂肪酸、グリセリンや１，３−ブタンジオール等の多価アルコール類、非イオン界面活性剤、アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、エタノール、カーボポール等の増粘剤、防腐剤、紫外線吸収剤、抗酸化剤、色素、粉体類等が例示できる。これらの上記抗真菌剤と任意成分とを常法に従って処理することにより、本発明の医薬組成物は製造することが出来る。
【００１７】
【化１９】
【００１８】
【化２０】
【００１９】
【化２１】
【００２０】
【実施例】
以下に、実施例を挙げて、本発明について更に詳細に説明を加えるが、本発明がこれら実施例にのみ限定を受けないことは言うまでもない。
【００２１】
＜実施例１＞
Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物１）の合成
［工程Ａ］
Ｎ−（ｐ−ターシャリー−ブチルベンジル）メチルアミンの０．５ｇをＮ，Ｎ−ジメチルホルムアミド（以下、ＤＭＦ）１０ｍｌに溶解させ、炭酸ナトリウムを０．５ｇを混合し、これにＤＭＦ５ｍｌに２−ブロモ−３’（トリフルオロメチル）アセトフェノン０．７ｇを溶かした液を、室温で攪拌しながら滴下した。３時間攪拌した後、氷と飽和炭酸水素ナトリウム水溶液の上に、この反応液を一気に注いだ。酢酸エチル１００ｍｌで抽出し、炭酸水素ナトリウム水溶液、次いで飽和食塩水溶液で洗浄した。硫酸ナトリウムで乾燥した後、減圧濃縮し、シリカゲルカラムクロマトグラフィー（溶出溶媒；ｎ−ヘキサン：酢酸エチル＝１０：１）で精製し、化合物４を黄色油状物質として得た。（収率６９．４％）このものの1Ｈ−ＮＭＲは次に示すとおりである。（溶媒；ＣＤＣｌ3、δｐｐｍ、以下に示すＮＭＲの数値は同様のものを示す。）
１．３１（ｓ，９Ｈ）、２．５３（ｓ，３Ｈ）、３．６３（ｓ，２Ｈ）、３．７３（ｓ，２Ｈ）、７．２４〜７．３５（ｍ，４Ｈ），７．５２〜７．８４（ｍ，２Ｈ）、８．１２〜８．３６（ｍ，２Ｈ）
【００２２】
［工程Ｂ］
ベンゼン１０ｍｌにメチルトリフェニルホスホニウムブロミド０．８ｇを懸濁させ、窒素雰囲気下室温で攪拌しながら、１．６３Ｍのｎ−ブチルリチウムヘキサン溶液１．４ｍｌを加えた。５分間攪拌した後、化合物４の０．４６ｇをベンゼン５ｍｌに溶かした液を滴下した。室温で１晩攪拌した後、氷水の上に注ぎ反応を止めた。これよりベンゼン１００ｍｌで抽出し、飽和食塩水で洗い、硫酸ナトリウムで乾燥させ、減圧濃縮し、これをシリカゲルカラムクロマトグラフィー（溶出溶媒；ヘキサン：酢酸エチル＝２０：１）で精製し、淡黄色の油状物質として化合物１を得た。（収率３３．２％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．１６（ｓ，３Ｈ）、３．３５（ｓ，２Ｈ）、３．４８（ｓ，２Ｈ）、５．３３（ｓ，１Ｈ）、５．５０（ｓ，１Ｈ）、７．１６（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）、７．３２（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）、７．４１（ｄｄ，１Ｈ，Ｊ＝７．８３Ｈｚ，７．８３Ｈｚ），７．５２（ｄ，１Ｈ，Ｊ＝７．８３）、７．６１（ｄ，１Ｈ，Ｊ＝７．８３Ｈｚ）、７．７３（ｓ，１Ｈ）
【００２３】
［工程Ｃ］
化合物１の０．０４ｇをイソプロピルエーテル５０ｍｌに溶解させ、室温で攪拌しながら４Ｎ−ＨＣｌ酢酸エチル溶液０．０４ｍｌを加えた。室温で一晩攪拌し後、析出した白色結晶を濾取し、乾燥させ、収率７３．２％で化合物１の塩酸塩を得た。このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．６０（ｄ，３Ｈ，Ｊ＝４．５９Ｈｚ）、３．９５〜４．２１（ｍ，４Ｈ）、５．９４（ｓ，１Ｈ）、６．０７（ｓ，１Ｈ）、７．４２〜７．６６（ｍ，８Ｈ）、１２．８（ｂｓ，１Ｈ）
【００２４】
又、融点は１７８．５〜１８２℃であり、赤外スペクトルは次に示すとおりである。（単位はｃｍ-1）
３４２７、２９６９、２６９１、１４７６、１３９３、１３３９、１３０５、１２７１、１１６７、１１２８
【００２５】
＜実施例２＞
トランス−Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物２）
実施例１の出発物質のＮ−（ｐ−ターシャリー−ブチルベンジル）メチルアミンをトランス−Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）メチルアミンに変え、工程Ａを行い、化合物５を黄色油状物質として得た。（収率３４．８％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．２３（ｓ，９Ｈ）、２．３９（ｓ，３Ｈ）、３．２０（ｄｄ，２Ｈ，Ｊ＝１．３５Ｈｚ、６．７５Ｈｚ）、３．８０（ｓ，２Ｈ）、５．６６（ｔｄ，１Ｈ，Ｊ＝１．３５Ｈｚ、１７．３Ｈｚ）、６．０７（ｔｄ，１Ｈ，Ｊ＝６．７５Ｈｚ、１７．３Ｈｚ）、７．６０（ｄｄ，１Ｈ，Ｊ＝７．８３Ｈｚ、７．８３Ｈｚ）、７．８２（ｄ，１Ｈ，Ｊ＝７．８３Ｈｚ）、８．２１（ｄ，１Ｈ，Ｊ＝７．８３Ｈｚ）、８．３５（ｓ，１Ｈ）
【００２６】
この化合物５を実施例１の工程Ｂと同様の操作を行い、化合物２を得た。（収率１８．９％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．２４（ｓ，９Ｈ）、２．１８（ｓ，３Ｈ）、３．０４（ｄ，２Ｈ，Ｊ＝６．４８Ｈｚ）、３．３４（ｓ，２Ｈ）、５．３１（ｓ，１Ｈ）、５．５０（ｓ，１Ｈ）、５．６２（ｄ，１Ｈ，Ｊ＝１５．７Ｈｚ）、６．０３（ｔｄ，１Ｈ，Ｊ＝６．４８Ｈｚ、１５．７Ｈｚ）、７．４３（ｄｄ，１Ｈ，Ｊ＝７．５６Ｈｚ、８．１０Ｈｚ）、７．５２（ｄ，１Ｈ，Ｊ＝７．５６Ｈｚ）、７．６７（ｄ，１Ｈ，Ｊ＝８．１０Ｈｚ）
【００２７】
実施例１の工程Ｃと同様の操作を行い、化合物２の塩酸塩を作成した。（収率６０．１％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．２３（ｓ，９Ｈ）、２．６３（ｄ，３Ｈ，Ｊ＝４．８６Ｈｚ）、３．４９〜３．６３（ｍ，２Ｈ）、３．９８〜４．１９（ｍ，２Ｈ）、５．６９（ｄ，１Ｈ，Ｊ＝１５．７Ｈｚ）、６．２２（ｔｄ，１Ｈ，Ｊ＝７．２９Ｈｚ、１５．７Ｈｚ）、７．５４〜７．６７（ｍ，４Ｈ）、１３．０（ｂｓ，１Ｈ）
【００２８】
このもの融点は１６４〜１６５．５℃であり、赤外吸収スペクトルは次の通りである。（単位はｃｍ-1）
３４４４、２９７３、２６２６、１３３７、１１６５、１１２９、１０７４
【００２９】
＜実施例３＞
Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−（２，５−ジフルオロフェニル）−２−プロペニルアミン（化合物３）
実施例１の出発物質の２−ブロモ−３’−（トリフルオロメチル）アセトフェノンを２−ブロモ−２’，５’−ジフルオロアセトフェノンに変え、同様に工程Ａの処理して化合物６を黄色油状物質として得た。（収率３４．８％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．３６（ｓ，３Ｈ）、３．６８（ｓ，２Ｈ）、３．７９（ｄ，２Ｈ，Ｊ＝２．９７Ｈｚ）、７．０５〜７．１５（ｍ，２Ｈ）、７．１９（ｄ，２Ｈ，Ｊ＝８．６４Ｈｚ）、７．３０（ｄ，２Ｈ，Ｊ＝８．６４Ｈｚ）、７．４５〜７．５１（ｍ，１Ｈ）
【００３０】
この化合物６を実施例１の工程Ｂと同様の操作を行い、化合物３を得た。（収率１９．５％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．３０（ｓ，９Ｈ）、２．１５（ｓ，３Ｈ）、３．３３（ｓ，２Ｈ）、３．４５（ｓ，２Ｈ）、５．４１（ｓ，１Ｈ）、５．４９（ｓ，１Ｈ）、６．９２〜７．０４（ｍ，３Ｈ）、７．０８（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）、７．２８（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）
【００３１】
実施例１の工程Ｃと同様の操作を行い、化合物３の塩酸塩を作成した。（収率９０．１％）このものの1Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．６３（ｄ，３Ｈ，Ｊ＝５．１３Ｈｚ）、３．８９〜４．２０（ｍ，４Ｈ）、５．８４（ｓ，１Ｈ）、６．１８（ｓ，１Ｈ）、６．８９〜７．１６（ｍ，３Ｈ）、７．４２（ｄ，２Ｈ，Ｊ＝８．９１Ｈｚ）、７．４６（ｄ，２Ｈ，Ｊ＝８．９１Ｈｚ）、１２．７（ｂｓ，１Ｈ）
【００３２】
このもの融点は１４５〜１４７℃であり、赤外吸収スペクトルは次の通りである。（単位はｃｍ-1）
３４５４、２９６４、１４９３、１４６７、１４２５、１１８７
【００３３】
＜実施例４＞
抗菌性試験（発育阻止濃度の測定）
トリコフィトンに対する本発明の化合物の抗真菌作用を求めた。即ち、トリコフィトン・メンタグロファイテス（T.mentagrophytes TIMM1189）を予めサブロー寒天培地の斜面に２７℃で２週間培養して分生子を充分つくらせる。これをツィーン８０を０．０５重量／容量％含有する滅菌生理食塩水で白金耳で擦りながら洗浄し分生子を浮遊させる。これを二枚重ねのガーゼで濾過し分生子のみを生理食塩水に浮遊する形で取り出した。分生子の濃度を１０5個／ｍｌになるように調整し試験菌菌液とした。一方、化合物を４ｍｇとり、ジメチルスルホキサイド１ｍｌを加え原液とし、これを順次ジメチルスルホキサイドで２倍希釈し希釈薬剤液を調整した。組織培養用９６穴マイクロプレートの各ウェルにサブロー・デキストロース培地１７５μｌ、薬剤溶液５μｌ、試験菌菌液２０μｌを加え、良く混和した後、２７℃で１週間培養し目視にて完全に発育を阻止する最小濃度を探し、最小発育阻止濃度とした。結果は、化合物１の塩酸塩が３．１２μｇ／ｍｌであり、化合物２の塩酸塩が３．１２μｇ／ｍｌであり、化合物３の塩酸塩が０．２５μｇ／ｍｌであった。これより本発明の抗真菌剤の抗真菌作用が優れていることがわかる。
【００３４】
＜実施例５＞
下記に示す処方に従って本発明の医薬組成物である、水虫治療用の軟膏を作成した。即ち、処方成分をニーダーに秤込み混練りして軟膏を得た。
ワセリン ９９重量部
化合物１の塩酸塩 １重量部
【００３５】
＜実施例６＞
下記に示す処方に従って本発明の医薬組成物である、水虫治療用の軟膏を作成した。即ち、処方成分をニーダーに秤込み混練りして軟膏を得た。
ワセリン ９９重量部
化合物２の塩酸塩 １重量部
【００３６】
＜実施例７＞
下記に示す処方に従って本発明の医薬組成物である、水虫治療用の軟膏を作成した。即ち、処方成分をニーダーに秤込み混練りして軟膏を得た。
ワセリン ９９重量部
化合物３の塩酸塩 １重量部
【００３７】
【発明の効果】
本発明によれば、抗真菌作用を有する新規母核の化合物が提供できる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a novel fluorine-containing compound suitable for an antifungal agent.
[0002]
[Prior art]
Superficial mycosis, such as athlete's foot, has been overcome in the present age, because there are still no reliable treatments and drugs available, coupled with the fact that life has become westernized and shoe wear has increased. It is counted as one of the diseases that have not been done. Therefore, many compounds have been screened for antifungal activity. However, there are not many substances that have been found to be active in vitro or at the animal level but drop out in the actual clinical stage, and very few results have been obtained so far. That is, the discovery of a mother nucleus having a novel antifungal action has been awaited. This situation is not limited to superficial fungi, but amphotericin B, which is extremely toxic and has little effect on deep fungal diseases such as Candida albicans and Aspergillus niger, must be used. There is no extremely serious situation. That is, development of an antifungal agent having a novel mother nucleus has been desired.
[0003]
On the other hand, any of the compounds represented by the general formula (I) to be described later is a compound not described in any literature, and therefore it has not been known at all that such a compound has an excellent antifungal action.
[0004]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and an object of the present invention is to find a novel mother nucleus compound having an antifungal action.
[0005]
[Means for solving problems]
In view of such a situation, as a result of intensive research efforts to find a novel mother nucleus compound having antifungal activity, the present inventors have found that the compound represented by the general formula (I), particularly the general formula (II) ) And / or physiologically acceptable salts thereof have found such an action, and have completed the invention. Hereinafter, the present invention will be described in detail with a focus on embodiments.
[0006]
Embedded image
(In the formula, R1 represents an aromatic hydrocarbon group containing a fluorine atom, R2 represents an alkyl group having 1 to 4 carbon atoms, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0007]
Embedded image
(In the formula, X represents a fluorine atom or a trifluoromethyl group, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0008]
DETAILED DESCRIPTION OF THE INVENTION
(1) Compound represented by general formula (III) and / or general formula (IV) of the present invention The compound represented by general formula (III) and / or general formula (IV) of the present invention is represented by the general formula ( It is an important reaction intermediate in the preparation of compounds of I) and / or general formula (II). By subjecting this to the Wittig reaction, the compounds represented by the general formulas (I) to (II) of the present invention can be produced. In the present invention, among the compounds represented by the general formula (III), the compound of the general formula (IV) in which the side chain is specified is particularly preferable. As the halogen atom, a chlorine atom is particularly preferable. Also, as shown in Reaction Scheme 1, this compound is acetylated in the presence of a Lewis acid in the presence of an aromatic compound or its halide, and then the methyl hydrogen atom of this acetyl group is replaced with a halogen atom. It can be produced by condensation with an amine in the presence of an alkali. These compounds are all novel compounds not described in any literature. Particularly preferred as such a compound of the present invention is 2- [N- (4-tertiary-butylbenzyl) -N-methylamino] -3 ′-(trifluoromethyl) acetophenone (compound 4), Trans-2- [N- (6,6-dimethyl-2-hepten-4-ynyl) methylamino] -3 '-(trifluoromethyl) acetophenone (compound 5) and 2- [N- (4-tertiary) -Butylbenzyl) -N-methylamino] -2 ', 5'-difluoroacetophenone (compound 6).
[0009]
Embedded image
(In the formula, R1 represents an aromatic hydrocarbon group containing a fluorine atom, R2 represents an alkyl group having 1 to 4 carbon atoms, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0010]
Embedded image
(In the formula, X represents a fluorine atom or a trifluoromethyl group, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0011]
Embedded image
[0012]
Embedded image
[0013]
Embedded image
[0014]
Embedded image
(In the formula, X represents a fluorine atom or a trifluoromethyl group, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0015]
(2) Compounds represented by general formula (I) and general formula (II) of the present invention The compounds represented by general formula (I) and general formula (II) of the present invention are represented by the above general formula (III), It can be obtained by treating the compound represented by the general formula (IV) with methyltriphenylphosphonium bromide and butyl lithium, that is, subjecting it to a Wittig reaction. In the present invention, among the compounds represented by the general formula (I), a limited compound group represented by the general formula (II) is preferable. Furthermore, as a form of the fluorine atom, it is preferable to use the fluorine atom itself as a substituent or use a trifluoromethyl group as a substituent. This is because such a group of compounds has excellent antifungal activity. A specific example of such a compound is N- (4-tertiary-butylbenzyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 1). , Trans-N- (6,6-dimethyl-2-hepten-4-ynyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (compound 2), N- ( Examples include 4-tertiary-butylbenzyl) -N-methyl-2- (2,5-difluorophenyl) -2-propenylamine (Compound 3). These can be led to salts according to conventional methods. That is, a salt can be formed by adding a corresponding acid in an aqueous or non-aqueous solvent. Examples of preferred salts in the present invention include mineral acid salts such as hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid, and organic acid salts such as acetic acid, oxalic acid, maleic acid and fumaric acid. Is particularly preferred. This is because it is excellent in stability and economy. The compounds represented by the general formula (I) and / or the general formula (II) thus obtained and / or their salts can be used as the antifungal agent of the present invention because they have an excellent antifungal action. Moreover, since the antifungal agent of this invention is excellent also in safety, the administration route is not ask | required. The dose of the compound of the present invention as an antifungal agent varies depending on the patient's condition and symptoms. For example, in the case of oral administration or administration by injection, 1 to 10000 mg daily for adults may be once or several times. It is preferably administered separately, and if it is an external preparation for skin, it is preferable to apply an appropriate amount containing 0.1 to 10% by weight, and if it is a vaginal suppository, it contains 0.1 to 10% by weight. Is preferably administered once or several times.
[0016]
(3) Pharmaceutical composition of the present invention The pharmaceutical composition of the present invention is characterized by containing the antifungal agent of the present invention. As shown in the examples below, the antifungal agent of the present invention has an excellent antifungal action, so that the pharmaceutical composition of the present invention is used to treat superficial mycosis or deep mycosis, prevent deterioration, and relapse. It is very useful for prevention. Preferred examples of the pharmaceutical composition of the present invention include external preparations for skin such as liquids, creams and ointments, oral preparations such as tablets, capsules and powders, injections and vaginal suppositories. In addition to the above antifungal agents, the pharmaceutical composition of the present invention can contain optional components usually used in pharmaceutical compositions. Examples of such optional components include, for example, oral preparations and injections, excipients, binders, coating agents, lubricants, sugar coatings, disintegrating agents, extenders, flavoring agents, emulsification / solubilization. -Dispersants, stabilizers, pH adjusters, isotonic agents, etc. can be exemplified. For skin external preparations and vaginal suppositories, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax , Triglycerides such as beef tallow and olive oil, higher alcohols such as cetanol and oleyl alcohol, fatty acids such as stearic acid and oleic acid, polyhydric alcohols such as glycerin and 1,3-butanediol, nonionic surfactants, Examples include anionic surfactants, cationic surfactants, amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, dyes, powders, and the like. The pharmaceutical composition of the present invention can be produced by treating these antifungal agents and optional components according to a conventional method.
[0017]
Embedded image
[0018]
Embedded image
[0019]
Embedded image
[0020]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples, but it goes without saying that the present invention is not limited only to these examples.
[0021]
<Example 1>
Synthesis of N- (4-tertiary-butylbenzyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 1) [Step A]
0.5 g of N- (p-tertiary-butylbenzyl) methylamine is dissolved in 10 ml of N, N-dimethylformamide (hereinafter DMF), 0.5 g of sodium carbonate is mixed, and this is mixed with 5 ml of DMF. A solution in which 0.7 g of bromo-3 ′ (trifluoromethyl) acetophenone was dissolved was added dropwise with stirring at room temperature. After stirring for 3 hours, the reaction solution was poured all at once onto ice and saturated aqueous sodium hydrogen carbonate solution. The mixture was extracted with 100 ml of ethyl acetate and washed with an aqueous sodium hydrogen carbonate solution and then with a saturated saline solution. The extract was dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (elution solvent; n-hexane: ethyl acetate = 10: 1) to give compound 4 as a yellow oil. (Yield: 69.4%) 1 H-NMR of this product is as shown below. (Solvent: CDCl 3 , δ ppm, NMR values shown below are the same)
1.31 (s, 9H), 2.53 (s, 3H), 3.63 (s, 2H), 3.73 (s, 2H), 7.24 to 7.35 (m, 4H), 7 .52 to 7.84 (m, 2H), 8.12 to 8.36 (m, 2H)
[0022]
[Step B]
In 10 ml of benzene, 0.8 g of methyltriphenylphosphonium bromide was suspended, and 1.4 ml of a 1.63 M n-butyllithium hexane solution was added while stirring at room temperature under a nitrogen atmosphere. After stirring for 5 minutes, a solution prepared by dissolving 0.46 g of Compound 4 in 5 ml of benzene was added dropwise. After stirring overnight at room temperature, the reaction was stopped by pouring onto ice water. This was extracted with 100 ml of benzene, washed with saturated brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (elution solvent; hexane: ethyl acetate = 20: 1) to give a pale yellow Compound 1 was obtained as an oily substance. (Yield 33.2%) 1 H-NMR of this product is as follows.
1.31 (s, 9H), 2.16 (s, 3H), 3.35 (s, 2H), 3.48 (s, 2H), 5.33 (s, 1H), 5.50 (s) , 1H), 7.16 (d, 2H, J = 8.37 Hz), 7.32 (d, 2H, J = 8.37 Hz), 7.41 (dd, 1H, J = 7.83 Hz, 7. 83 Hz), 7.52 (d, 1H, J = 7.83), 7.61 (d, 1H, J = 7.83 Hz), 7.73 (s, 1H)
[0023]
[Step C]
0.04 g of Compound 1 was dissolved in 50 ml of isopropyl ether, and 0.04 ml of 4N-HCl ethyl acetate solution was added with stirring at room temperature. After stirring at room temperature overnight, the precipitated white crystals were collected by filtration and dried to obtain the hydrochloride of compound 1 in a yield of 73.2%. 1 H-NMR of this product is as follows.
1.31 (s, 9H), 2.60 (d, 3H, J = 4.59 Hz), 3.95 to 4.21 (m, 4H), 5.94 (s, 1H), 6.07 ( s, 1H), 7.42-7.66 (m, 8H), 12.8 (bs, 1H)
[0024]
Moreover, melting | fusing point is 178.5-182 degreeC and an infrared spectrum is as showing next. (Unit is cm -1 )
3427, 2969, 2691, 1476, 1393, 1339, 1305, 1271, 1167, 1128
[0025]
<Example 2>
Trans-N- (6,6-Dimethyl-2-hepten-4-ynyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 2)
The starting material N- (p-tertiary-butylbenzyl) methylamine of Example 1 was changed to trans-N- (6,6-dimethyl-2-hepten-4-ynyl) methylamine, and step A was performed. Compound 5 was obtained as a yellow oil. (Yield 34.8%) 1 H-NMR of this product is as follows.
1.23 (s, 9H), 2.39 (s, 3H), 3.20 (dd, 2H, J = 1.35 Hz, 6.75 Hz), 3.80 (s, 2H), 5.66 ( td, 1H, J = 1.35 Hz, 17.3 Hz), 6.07 (td, 1H, J = 6.75 Hz, 17.3 Hz), 7.60 (dd, 1H, J = 7.83 Hz, 7. 83 Hz), 7.82 (d, 1H, J = 7.83 Hz), 8.21 (d, 1H, J = 7.83 Hz), 8.35 (s, 1H)
[0026]
This compound 5 was treated in the same manner as in step B of Example 1 to obtain compound 2. (Yield 18.9%) 1 H-NMR of this product is as follows.
1.24 (s, 9H), 2.18 (s, 3H), 3.04 (d, 2H, J = 6.48 Hz), 3.34 (s, 2H), 5.31 (s, 1H) 5.50 (s, 1H), 5.62 (d, 1H, J = 15.7 Hz), 6.03 (td, 1H, J = 6.48 Hz, 15.7 Hz), 7.43 (dd, 1H, J = 7.56 Hz, 8.10 Hz), 7.52 (d, 1 H, J = 7.56 Hz), 7.67 (d, 1 H, J = 8.10 Hz)
[0027]
The same operation as in Step C of Example 1 was performed to prepare the hydrochloride of compound 2. (Yield 60.1%) 1 H-NMR of this product is as shown below.
1.23 (s, 9H), 2.63 (d, 3H, J = 4.86 Hz), 3.49 to 3.63 (m, 2H), 3.98 to 4.19 (m, 2H), 5.69 (d, 1H, J = 15.7 Hz), 6.22 (td, 1H, J = 7.29 Hz, 15.7 Hz), 7.54 to 7.67 (m, 4H), 13.0 (Bs, 1H)
[0028]
Its melting point is 164-1655 ° C., and its infrared absorption spectrum is as follows. (Unit is cm -1 )
3444, 2973, 2626, 1337, 1165, 1129, 1074
[0029]
<Example 3>
N- (4-tertiary-butylbenzyl) -N-methyl-2- (2,5-difluorophenyl) -2-propenylamine (Compound 3)
The starting material 2-bromo-3 ′-(trifluoromethyl) acetophenone of Example 1 was changed to 2-bromo-2 ′, 5′-difluoroacetophenone and treated in the same manner as in step A to give compound 6 as a yellow oil Got as. (Yield 34.8%) 1 H-NMR of this product is as follows.
1.31 (s, 9H), 2.36 (s, 3H), 3.68 (s, 2H), 3.79 (d, 2H, J = 2.97 Hz), 7.05 to 7.15 ( m, 2H), 7.19 (d, 2H, J = 8.64 Hz), 7.30 (d, 2H, J = 8.64 Hz), 7.45 to 7.51 (m, 1H)
[0030]
This compound 6 was subjected to the same operation as in step B of Example 1 to obtain compound 3. (Yield 19.5%) 1 H-NMR of this product is as follows.
1.30 (s, 9H), 2.15 (s, 3H), 3.33 (s, 2H), 3.45 (s, 2H), 5.41 (s, 1H), 5.49 (s) , 1H), 6.92 to 7.04 (m, 3H), 7.08 (d, 2H, J = 8.37 Hz), 7.28 (d, 2H, J = 8.37 Hz)
[0031]
The same operation as in Step C of Example 1 was performed to prepare the hydrochloride of compound 3. (Yield 90.1%) 1 H-NMR of this product is as shown below.
1.31 (s, 9H), 2.63 (d, 3H, J = 5.13 Hz), 3.89 to 4.20 (m, 4H), 5.84 (s, 1H), 6.18 ( s, 1H), 6.89 to 7.16 (m, 3H), 7.42 (d, 2H, J = 8.91 Hz), 7.46 (d, 2H, J = 8.91 Hz), 12. 7 (bs, 1H)
[0032]
Its melting point is 145 to 147 ° C., and its infrared absorption spectrum is as follows. (Unit is cm -1 )
3454, 2964, 1493, 1467, 1425, 1187
[0033]
<Example 4>
Antibacterial test (measurement of growth inhibitory concentration)
The antifungal action of the compounds of the present invention on trichophyton was determined. That is, Trichophyton mentagrophytes (T.mentagrophytes TIMM1189) is cultured in advance on a slope of Sabouraud's agar medium at 27 ° C. for 2 weeks to sufficiently produce conidia. This is washed with a sterilized physiological saline containing 0.05 wt / vol% of Tween 80 while rubbing with a platinum loop to float the conidia. This was filtered through two layers of gauze and only the conidia were taken out in a form floating in physiological saline. The concentration of conidia was adjusted to 10 5 cells / ml to obtain a test bacterial cell solution. On the other hand, 4 mg of the compound was taken, and 1 ml of dimethyl sulfoxide was added to make a stock solution. Add 175 μl of Sabouraud dextrose medium, 5 μl of the drug solution, and 20 μl of the test bacterial solution to each well of a 96-well microplate for tissue culture, mix well, then incubate at 27 ° C. for 1 week to completely prevent growth. The minimum concentration was searched and used as the minimum growth inhibitory concentration. As a result, the hydrochloride of compound 1 was 3.12 μg / ml, the hydrochloride of compound 2 was 3.12 μg / ml, and the hydrochloride of compound 3 was 0.25 μg / ml. This shows that the antifungal action of the antifungal agent of the present invention is excellent.
[0034]
<Example 5>
An ointment for treating athlete's foot, which is a pharmaceutical composition of the present invention, was prepared according to the formulation shown below. That is, the prescription ingredients were weighed into a kneader and kneaded to obtain an ointment.
Petrolatum 99 parts by weight Compound 1 hydrochloride 1 part by weight
<Example 6>
An ointment for treating athlete's foot, which is a pharmaceutical composition of the present invention, was prepared according to the formulation shown below. That is, the prescription ingredients were weighed into a kneader and kneaded to obtain an ointment.
Vaseline 99 parts by weight Compound 2 hydrochloride 1 part by weight
<Example 7>
An ointment for treating athlete's foot, which is a pharmaceutical composition of the present invention, was prepared according to the formulation shown below. That is, the prescription ingredients were weighed into a kneader and kneaded to obtain an ointment.
Vaseline 99 parts by weight Compound 3 hydrochloride 1 part by weight
【The invention's effect】
According to the present invention, a novel mother nucleus compound having an antifungal action can be provided.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23355798A JP3805900B2 (en) | 1998-08-05 | 1998-08-05 | Antifungal agent and composition containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23355798A JP3805900B2 (en) | 1998-08-05 | 1998-08-05 | Antifungal agent and composition containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000053621A JP2000053621A (en) | 2000-02-22 |
| JP3805900B2 true JP3805900B2 (en) | 2006-08-09 |
Family
ID=16956942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23355798A Expired - Fee Related JP3805900B2 (en) | 1998-08-05 | 1998-08-05 | Antifungal agent and composition containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3805900B2 (en) |
-
1998
- 1998-08-05 JP JP23355798A patent/JP3805900B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000053621A (en) | 2000-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1373219A1 (en) | Thiohydantoins and use thereof for treating diabetes | |
| FR2562889A1 (en) | PHENETHANOLAMINE COMPOUNDS. PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | |
| EP1546111A2 (en) | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes | |
| JPH02290841A (en) | Novel compound, its production, and pharmaceutical composition containing the same | |
| JP3857429B2 (en) | Sulfur-containing antifungal agent | |
| EP0087378B1 (en) | Oxime-ethers of alkylamino alcohols as medicaments, compounds and process for their preparation | |
| JPH0717589B2 (en) | Novel 1,3-dicarbonyl compound and composition thereof | |
| JPS62108814A (en) | Lipid peroxide production inhibitor | |
| EP0539281B1 (en) | Naphthamides, process for their preparation and their application in the therapeutical field | |
| JPS5942372A (en) | Substituted phenothiazine derivative | |
| FR2845384A1 (en) | New 2-thiohydantoin derivatives used for treating diabetes, hyperglycemic disorders, obesity, cerebral ischemia and cerebral vascular accidents | |
| CH648827A5 (en) | SUBSTITUTED HETEROCYCLIC PHENOXYAMINES, THEIR PREPARATION AND MEDICAMENTS CONSISTING OF OR COMPRISING SUCH COMPOUNDS. | |
| JP2002538101A (en) | Use of polycyclic thiazoles in the manufacture of a medicament for preventing or treating obesity | |
| JP3805900B2 (en) | Antifungal agent and composition containing the same | |
| CA2045849A1 (en) | Oxazolopyridines derivatives, their preparation process and pharmaceutical compositions containing them | |
| FR2669633A1 (en) | NOVEL BENZOSELENAZOLINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| KR100195648B1 (en) | Substituted Aminoalkylbenzene Derivatives | |
| JP3857428B2 (en) | Antifungal agent | |
| JP3805901B2 (en) | Aromatic antifungal agent | |
| FR2653767A1 (en) | 1- (AMINOPHENYL) -2-PIPERIDINOPROPANONE DERIVATIVES, METHOD AND USE IN THERAPEUTICS. | |
| JP3805905B2 (en) | Aromatic antifungal agent | |
| FR2470110A1 (en) | DECRAPENYLAMINE DERIVATIVES, THEIR ACID ADDITION SALTS AND PHARMACEUTICAL COMPOSITION COMPRISING THESE PRODUCTS | |
| JP3776155B2 (en) | Benzophenone derivative and composition containing the same | |
| JP3839518B2 (en) | Antifungal | |
| JP3650206B2 (en) | Antifungal agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060509 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060511 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |